Aarti Drugs Limited (AARTIDRUGS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) has a cash flow conversion efficiency ratio of 0.104x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs1.52 Billion ≈ $16.48 Million USD) by net assets (Rs14.69 Billion ≈ $158.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aarti Drugs Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Aarti Drugs Limited - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Aarti Drugs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aarti Drugs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aarti Drugs Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agro Tech Foods Limited
NSE:ATFL
|
0.022x |
|
SNDL Inc.
NASDAQ:SNDL
|
0.029x |
|
Shenyang Chemical Industry Co Ltd
SHE:000698
|
0.142x |
|
Hyundai Green Food Co. Ltd.
KO:453340
|
0.048x |
|
29METALS Ltd
AU:29M
|
0.051x |
|
Proact IT Group AB
ST:PACT
|
0.129x |
|
Radium Life Tech Co Ltd
TW:2547
|
0.025x |
|
HannsTouch Solution Inc
TW:3049
|
-0.043x |
Annual Cash Flow Conversion Efficiency for Aarti Drugs Limited (2007–2025)
The table below shows the annual cash flow conversion efficiency of Aarti Drugs Limited from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see AARTIDRUGS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs13.69 Billion ≈ $148.09 Million |
Rs2.45 Billion ≈ $26.45 Million |
0.179x | -36.21% |
| 2024-03-31 | Rs12.82 Billion ≈ $138.64 Million |
Rs3.59 Billion ≈ $38.82 Million |
0.280x | +148.83% |
| 2023-03-31 | Rs11.93 Billion ≈ $128.98 Million |
Rs1.34 Billion ≈ $14.51 Million |
0.113x | +67.45% |
| 2022-03-31 | Rs10.36 Billion ≈ $112.07 Million |
Rs696.36 Million ≈ $7.53 Million |
0.067x | -60.36% |
| 2021-03-31 | Rs9.13 Billion ≈ $98.78 Million |
Rs1.55 Billion ≈ $16.75 Million |
0.170x | -55.88% |
| 2020-03-31 | Rs6.52 Billion ≈ $70.56 Million |
Rs2.51 Billion ≈ $27.12 Million |
0.384x | +45.95% |
| 2019-03-31 | Rs5.43 Billion ≈ $58.77 Million |
Rs1.43 Billion ≈ $15.47 Million |
0.263x | +71.88% |
| 2018-03-31 | Rs4.55 Billion ≈ $49.25 Million |
Rs697.66 Million ≈ $7.54 Million |
0.153x | -63.96% |
| 2017-03-31 | Rs4.11 Billion ≈ $44.42 Million |
Rs1.75 Billion ≈ $18.88 Million |
0.425x | +13.96% |
| 2016-03-31 | Rs3.57 Billion ≈ $38.65 Million |
Rs1.33 Billion ≈ $14.42 Million |
0.373x | +9.88% |
| 2015-03-31 | Rs3.08 Billion ≈ $33.33 Million |
Rs1.05 Billion ≈ $11.31 Million |
0.339x | -10.76% |
| 2014-03-31 | Rs2.51 Billion ≈ $27.13 Million |
Rs954.26 Million ≈ $10.32 Million |
0.380x | +6.26% |
| 2013-03-31 | Rs2.08 Billion ≈ $22.45 Million |
Rs743.10 Million ≈ $8.04 Million |
0.358x | +72.40% |
| 2012-03-31 | Rs1.76 Billion ≈ $19.09 Million |
Rs366.41 Million ≈ $3.96 Million |
0.208x | +64.76% |
| 2011-03-31 | Rs1.63 Billion ≈ $17.65 Million |
Rs205.60 Million ≈ $2.22 Million |
0.126x | -68.79% |
| 2010-03-31 | Rs1.46 Billion ≈ $15.84 Million |
Rs591.20 Million ≈ $6.39 Million |
0.404x | -18.58% |
| 2009-03-31 | Rs1.23 Billion ≈ $13.35 Million |
Rs612.10 Million ≈ $6.62 Million |
0.496x | +94.81% |
| 2008-03-31 | Rs1.12 Billion ≈ $12.06 Million |
Rs283.87 Million ≈ $3.07 Million |
0.255x | -12.94% |
| 2007-03-31 | Rs1.00 Billion ≈ $10.83 Million |
Rs292.69 Million ≈ $3.17 Million |
0.292x | -- |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more